Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Executive Summary

Celgene will pay $9bn to buy the 90.3% of Juno that it doesn't already own, seeking to not only become a leader in the CAR-T field, but to increase its leadership in non-Hodgkin lymphoma, multiple myeloma, other hematological malignancies.


Related Content

Celgene Gives Reassurances That Key Products And Programs Remain On Track
Should Celgene Succumb To The Charms Of Juno?
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's Partnered Pipeline Delivers Successes And Setbacks
What's Gilead Getting From Kite For Nearly $12bn?
Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed
Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication
Celgene shows CAR-T confidence with $1bn Juno investment


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts